Blog posts for U.S. healthcare professionals, including physicians, prescribers and pharmacists.
Read the news release from Hikma Pharmaceuticals announcing the shelf-life extension of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg.
The science behind naloxone Drug overdose is the leading cause of unintentional death in the US, and most of these overdoses involve opioids.1 Naloxone is a life-saving medicine that [...]
Have you ever wondered what’s on the Surgeon General’s list of “the biggest killers out there?” In 2019, then-Surgeon General Jerome Adams gave a surprising answer: stigma.1 Although substance [...]
New video features patient voices. A new video from Hikma Community Health™* is a collection of comments researchers captured in 2021 while conducting the MORE study,† which showed multiple [...]
A new study from Hikma Community Health™* showed more than one 4 mg dose of naloxone nasal spray often is involved in an opioid overdose reversal incident.¹ The results of [...]
5 things you can do to support someone recovering from addiction. There are more than 23 million¹ Americans in recovery from addiction to alcohol and other drugs and another 100 [...]
National Fentanyl Prevention and Awareness Day, Aug. 21, was established in remembrance of loved ones who lost their lives to illicit fentanyl poisoning and to acknowledge the devastation this [...]
Opioid Patients Want to Talk About Naloxone As a healthcare professional, you’re no stranger to tough conversations. The hazards of smoking, obesity, UV exposure and so on are all [...]
Antidepressants and anti-anxiety medications can be life-changing treatments for millions of people.1 However, they can have unexpected and potentially risky interactions with other drugs.1,2 Has your doctor prescribed you [...]
Hikma Pharmaceuticals announced, on April 30, 2021, the US Food and Drug Administration (FDA) approval of Kloxxado® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication. This announcement [...]
Contraindications
Hypersensitivity to naloxone hydrochloride or to any of the other ingredients
Warnings and Precautions
Side Effects
The following serious side effect is discussed in the full Prescribing Information for KLOXXADO®:
Symptoms of sudden and severe opioid withdrawal resulting from the use of KLOXXADO® in someone regularly using opioids include: body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goosebumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramps, weakness and increased blood pressure.
Infants may have seizures, cry more than normal and have increased reflexes.
Some people may become aggressive after abrupt reversal of opioid overdose.
In two clinical studies, a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO®, one spray in one nostril. Side effects were reported in two subjects for each of the following: abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope.
These are not all of the possible side effects of KLOXXADO®. Contact your doctor for medical advice about side effects.
Pregnancy, Infancy and Breastfeeding, Children
Tell your doctor if you are pregnant or plan to become pregnant. If you are pregnant and opioid dependent, use of KLOXXADO® may cause withdrawal symptoms in you and your unborn baby. A healthcare provider should monitor you and your unborn baby right away after you use KLOXXADO®.
There is no information regarding the presence of naloxone in human milk, the effects of naloxone on the breastfed infant or on milk production.
If the primary concern is an infant at risk of an overdose, consider whether other naloxone-containing products may be more appropriate.
KLOXXADO® nasal spray is safe and effective in children for known or suspected opioid overdose.
Dosage and Administration
Do not attempt to prime or test-fire the device. Each KLOXXADO® Nasal Spray contains only 1 dose of medicine and cannot be reused. Read the “instructions for use” at the end of the Prescribing Information and Medication Guide for detailed information about the right way to use KLOXXADO® Nasal Spray.
Storage and Handling
Store KLOXXADO® at room temperature between 68°F to 77°F (20°C to 25°C). Do not expose to temperatures below 41°F (5°C) or above 104°F (40°C). Do not freeze KLOXXADO®. Keep KLOXXADO® in its box until ready to use. Protect from light. Replace KLOXXADO® before the expiration date on the box. Keep KLOXXADO® and all medicines out of the reach of children.
For more information, please see the full Prescribing Information and Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.
This website is intended for U.S. audiences
Customer Service: Phone 1-800-631-2174 | Email
© Hikma Pharmaceuticals USA Inc. All rights reserved.
KLOXXADO®️ is a registered trademark of Hikma Pharmaceuticals USA Inc.
Better Health. Within Reach. Every Day.®️ is a registered trademark of Hikma Pharmaceuticals PLC.
Emergent Devices Inc. is wholly owned subsidiary of Emergent BioSolutions Inc.
KLOXXADO® is manufactured by Hikma Pharmaceuticals USA Inc. Columbus, OH 43228, and distributed by Emergent Devices Inc. Plymouth Meeting, PA 19462.
PP-KLOX-US-00024
March 2025